Amphastar Q2 revenue rises 5% to $183.9 million; GAAP net income slips to $30.3 million
Amphastar reported second-quarter 2026 net revenues of $183.9 million, up 5% from $174.4 million a year earlier, and gross margin rose to 50.8% from 49.6%. GAAP net income fell slightly to $30.3 million, though diluted EPS rose to $0.67 from $0.64 on a lower share count, and income from operations declined to $39.7 million from $42.2 million. Shareholders face a $100.0 million milestone payment to Eli Lilly due in the third quarter of 2026.
Key points
- Net revenues $183.9 million vs. $174.4 million a year earlier; glucagon sales fell 42% to $11.9 million
- GAAP net income $30.3 million, or $0.67 diluted EPS, vs. $31.0 million, or $0.64, in Q2 2025
- Adjusted non-GAAP net income $40.8 million, or $0.91 per diluted share, vs. $0.85 a year earlier
- BAQSIMI first annual net sales milestone of $175.0 million triggers a $100.0 million payment to Lilly due Q3 2026
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.